Overview

The global Pyrogen Testing Market was valued at USD 1.61 billion in 2025 and is projected to reach USD 3.38 billion by 2034, growing at a CAGR of 8.6% during the forecast period (2026–2034). The market is driven by increasing pharmaceutical production, rising demand for biologics, and stringent regulatory requirements for product safety.

The market is shifting from animal-derived to animal-free methods. Regulators and pharmacopoeias now accept recombinant reagents, and the monocyte activation test is replacing the rabbit test for many products. Concerns about horseshoe crab populations, the supply of lysate and animal welfare policies push companies to validate alternatives.

Government agencies and pharmacopoeial bodies are accelerating the adoption of alternative pyrogen testing methods. The U.S. Pharmacopeia’s Chapter 86 on recombinant reagent-based bacterial endotoxin testing became official in May 2025. Meanwhile, the European Pharmacopoeia Commission moved to replace the rabbit pyrogen test and added recombinant factor C to its bacterial endotoxins chapter in November 2025. In 2026, the U.S. FDA and regulators from Australia, Canada, Japan, Switzerland, and the European Union completed a joint review of a recombinant endotoxin test, supporting broader global acceptance. By region, North America held the largest market share in 2025 and Asia-Pacific is expected to be the fastest-growing region during the forecast period. 

Market Size & Share

Market Dynamics

KEY MARKET TREND:

Shift from Animal-Derived to Recombinant and Cell-Based Methods Emerging as a Transformational Trend

• Pharmaceutical manufacturers are validating recombinant factor C and recombinant cascade reagents beside LAL, so they can reduce reliance on horseshoe crab blood and secure a stable reagent supply.
• The monocyte activation test is replacing the rabbit pyrogen test for drugs, vaccines and devices, because it uses human cells and can detect both endotoxin and non-endotoxin pyrogens.
• Suppliers are packaging tests into pre-loaded cartridges, automated readers and rapid kits, which cuts hands-on time and lets quality control labs test in-process samples closer to the production line.
• According to the U.S. FDA, international regulators approved a recombinant endotoxin testing protocol in June 2026 covering biological products across four therapy areas, supporting the Pyrogen Testing Market’s shift toward animal-free testing methods.

KEY MARKET DRIVER

Growth in Injectable Drugs, Biologics and Cell and Gene Therapies Driving Pyrogen Testing Demand

• Every injectable drug, vaccine, implant and many medical devices must pass endotoxin or pyrogen release tests, so rising production of these products lifts testing volumes directly.
• Biologics, vaccines and cell and gene therapies are made in complex processes with many raw materials, and each batch needs testing for pyrogens at several stages.
• Stricter regulatory expectations on sterile product quality and data integrity push manufacturers toward validated, traceable methods and automated test systems.
• Charles River launched the Endosafe Trillium rCR cartridge in January 2024, an animal-free endotoxin test using recombinant cascade reagent, and said a beta study of existing clients showed equivalence to LAL within that dataset.

KEY MARKET OPPORTUNITY

Rapid Cell-Based Assays and Testing of Advanced Therapies Creating Significant Opportunity

• Cell and gene therapies, vaccines and combination products often cannot be tested with standard LAL methods, which creates room for monocyte activation and other product-specific assays.
• Contract laboratories can win work from small and mid-sized biotechnology companies that lack in-house quality control, by offering validated recombinant and MAT testing with fast turnaround.
• Growing injectable and biosimilar production in Asia-Pacific and the Middle East creates demand for local suppliers, training and validated protocols that meet international standards.
• Lonza launched two rapid monocyte activation test systems in 2023, using an IL-6 ELISA kit that it said cuts testing time from two days to two hours and reduces hands-on work.

Pyrogen Testing Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Test Type

The LAL test held the largest market share in 2025, supported by its long-standing use in bacterial endotoxin testing, established validation procedures, and widespread adoption across pharmaceutical quality control laboratories. Its proven reliability, compatibility with existing laboratory instruments, and availability in gel-clot, turbidimetric, and chromogenic formats continue to strengthen its position. Additionally, established testing protocols, trained laboratory personnel, and familiarity with regulatory requirements make LAL testing a practical choice for routine quality control. The cost and time associated with validating alternative methods, modifying existing workflows, and retraining staff further support its continued adoption across pharmaceutical manufacturing and biologics production.

The recombinant Factor C assay is projected to grow at the fastest CAGR during the forecast period, driven by increasing demand for animal-free testing alternatives, growing concerns over horseshoe crab conservation, and rising acceptance of recombinant reagents. Its ability to detect bacterial endotoxins without relying on animal-derived lysate is encouraging pharmaceutical manufacturers to consider alternative testing approaches. Additionally, advancements in assay technology, expanding validation across pharmaceutical and biologic products, and increasing emphasis on sustainable laboratory practices are expected to accelerate adoption. As more laboratories integrate recombinant methods into their quality control workflows, the segment is expected to gain momentum during the forecast period.

Test Type categories include

                    ·           LAL Test (Dominating Segment)

                    ·           Recombinant Factor C Assay (Highest CAGR Segment)

                    ·           Monocyte Activation Test

                    ·           Rabbit Pyrogen Test

                    ·           Others

Analysis by Product

Consumables held the largest market share in 2025, supported by recurring demand for reagents, testing kits, cartridges, plates, and other disposable laboratory supplies. Routine testing of raw materials, water, in-process samples, and finished pharmaceutical products drives continuous replenishment throughout manufacturing. The need to maintain consistent testing accuracy, prevent cross-contamination, and comply with quality control procedures further sustains consumables demand. Additionally, the widespread use of established testing workflows and the requirement to replace reagents and disposable components after use reinforce recurring purchases, keeping consumables ahead of instruments and services.

Instruments are projected to grow at the fastest CAGR during the forecast period, driven by increasing automation, digitalisation, and demand for efficient, traceable testing workflows. Automated readers, cartridge-based platforms, and integrated software can reduce manual handling, improve testing consistency, and support audit-ready data management. The expansion of biologics manufacturing and cell and gene therapy production is also encouraging laboratories to invest in modern testing equipment. Furthermore, efforts to improve laboratory throughput, minimise human error, and strengthen data integrity are expected to accelerate instrument adoption during the forecast period.

Product categories include

                    ·           Consumables (Dominating Segment)

                    ·           Instruments (Highest CAGR Segment)

                    ·           Services

Analysis by Detection Method

Kinetic chromogenic methods held the largest market share in 2025, supported by their ability to deliver quantitative results, compatibility with automated laboratory systems, and established use in bacterial endotoxin testing. Their ability to measure changes in colour intensity enables consistent monitoring of endotoxin levels across pharmaceutical samples. These methods are widely used in quality control workflows for injectable medicines, medical devices, and biologics, where reliable and reproducible results are essential. Additionally, compatibility with microplate readers, established validation procedures, and integration into routine laboratory operations support their continued adoption over turbidimetric and gel-clot methods.

Fluorescence-based methods are projected to grow at the fastest CAGR during the forecast period, driven by increasing adoption of recombinant Factor C assays and growing demand for sensitive, animal-free testing approaches. These methods detect fluorescent signals generated during the reaction, enabling sensitive and quantitative measurement of bacterial endotoxins. Their compatibility with automated platforms, microplate-based workflows, and digital data analysis supports efficient testing and consistent results. As pharmaceutical laboratories increasingly validate recombinant assays for routine quality control, the demand for fluorescence-based methods is expected to accelerate, particularly as manufacturers seek alternatives to animal-derived reagents and more efficient testing workflows.

Detection Method categories include

                    ·           Kinetic Chromogenic (Dominating Segment)

                    ·           Kinetic Turbidimetric

                    ·           Gel-Clot

                    ·           Fluorescence-Based (Highest CAGR Segment)

                    ·           Others

Analysis by Application

Pharmaceuticals and biologics held the largest market share in 2025, supported by the extensive production of injectable medicines, vaccines, and biological products that require stringent pyrogen testing to ensure patient safety. Testing across water systems, raw materials, in-process samples, and finished products generates recurring demand throughout the manufacturing process. The need for reliable batch release, contamination control, and compliance with pharmaceutical quality standards further reinforces adoption. Additionally, established testing protocols, high-volume sterile manufacturing, and continuous production of complex biologics sustain demand for pyrogen testing across pharmaceutical facilities.

Cell and gene therapies are projected to grow at the fastest CAGR during the forecast period, driven by advances in personalised medicine and the increasing development of innovative biological treatments. These therapies often involve complex manufacturing processes, limited production batches, and stringent quality requirements, increasing the need for sensitive and reliable pyrogen detection. Their specialised product matrices can also create testing challenges, encouraging laboratories to evaluate alternative methods, including recombinant assays and monocyte activation tests. Growing clinical development, expanding treatment availability, and the need for rapid quality assessment are expected to accelerate pyrogen testing adoption in this application segment.

Application categories include

                    ·           Pharmaceuticals and Biologics (Dominating Segment)

                    ·           Medical Devices

                    ·           Cell and Gene Therapies (Highest CAGR Segment)

                    ·           Others

By Region

Pyrogen Testing Market Regional Analysis

Pyrogen Testing Market Share 2025, (CAGR)

North America

41%

South America

XX%

Europe

27%

Middle East Africa

XX%

Asia Pacific

XX%

Regional Analysis

North America held the largest market share in 2025, supported by its well-established pharmaceutical, biologics, vaccine, and medical device industries, alongside stringent regulatory requirements for sterile product safety. The United States leads regional demand through its extensive biopharmaceutical manufacturing base, strong research infrastructure, and regulatory emphasis on reliable pyrogen and endotoxin testing. Canada contributes through its growing biotechnology sector, vaccine development activities, and pharmaceutical quality control requirements. Mexico also supports regional market growth through pharmaceutical manufacturing, medical device production, and the expansion of healthcare-related manufacturing capabilities. Additionally, increasing adoption of recombinant testing methods, laboratory automation, and advanced biological therapies is expected to sustain demand for pyrogen testing across the region.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, supported by expanding pharmaceutical manufacturing, rising biologics production, and increasing demand for reliable quality control. China is strengthening its pharmaceutical and biotechnology industries, supported by domestic drug manufacturing and biosimilar development. India is expanding vaccine production, generic medicines, and biopharmaceutical manufacturing, increasing the need for routine pyrogen and endotoxin testing. Japan has an established pharmaceutical industry, advanced biotechnology research, and stringent quality standards that encourage the adoption of reliable testing methods. South Korea is advancing biologics, biosimilars, and innovative therapies, supported by investment in biotechnology manufacturing. Across these countries, growing production capabilities, improving regulatory practices, and increasing interest in recombinant and cell-based testing methods are expected to drive regional market growth.

Countries and Regions Covered

North America (Dominating Region)

o  United States (Largest Country Market)

o  Canada

o  Mexico

Europe

o  Germany (Largest Country Market)

o  United Kingdom

o  France

o  Italy

o  Rest of Europe

Asia-Pacific (Fastest Growing Region)

o  China (Largest Country Market)

o  India (Fastest-Growing Country Market)

o  Japan

o  South Korea

o  Rest of Asia-Pacific

Middle East & Africa

o  Saudi Arabia (Largest Country Market)

o  United Arab Emirates

o  Rest of Middle East & Africa

Latin America

o  Brazil (Largest Country Market)

o  Argentina

o  Rest of Latin America

Market Share

The Pyrogen Testing Market is consolidated, with a group of global life science companies supplying testing reagents and systems, alongside specialised contract testing laboratories and regional providers. Companies such as Charles River Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific, FUJIFILM Wako, Associates of Cape Cod, bioMérieux, GenScript and Essange Reagents compete through assay portfolios and testing technologies, while Eurofins Scientific, Almac Group, Sotera Health, WuXi AppTec, Pacific BioLabs and Wickham Laboratories provide specialised laboratory testing services. Key success factors include regulatory acceptance, validated testing methods, assay accuracy, supply reliability, automation and technical support. Leading companies are advancing recombinant endotoxin reagents, rapid cartridge-based assays and in-vitro pyrogen detection methods, including recombinant Factor C and Monocyte Activation Testing, while strengthening testing capabilities and production capacity.

Key Players

                    ·           Charles River Laboratories International, Inc. (US)

                    ·           Lonza Group AG (Switzerland)

                    ·           Merck KGaA (Germany)

                    ·           Thermo Fisher Scientific Inc. (US)

                    ·           FUJIFILM Wako Pure Chemical Corporation (Japan)

                    ·           Associates of Cape Cod, Inc. (US)

                    ·           bioMérieux SA (France)

                    ·           Eurofins Scientific SE (Luxembourg)

                    ·           GenScript Biotech Corporation (China)

                    ·           Almac Group (UK)

                    ·           Sotera Health Company (US)

                    ·           WuXi AppTec Co., Ltd. (China)

                    ·           Pacific BioLabs (US)

                    ·           Wickham Laboratories Limited (UK)

                    ·           Essange Reagents (Netherlands)

Recent Market Developments

• April 2026: Associates of Cape Cod received regulatory validation for its PyroSmart NextGen recombinant cascade reagent through Bayer’s contrast-media API approvals, supporting the adoption of recombinant reagents and strengthening demand for animal-free endotoxin testing in the Pyrogen Testing Market.
• September 2026: Eurofins highlighted the transition from the Rabbit Pyrogen Test (RPT) to the Monocyte Activation Test (MAT) following European regulatory changes, supporting demand for alternative in-vitro pyrogen testing methods in the Pyrogen Testing Market.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Pyrogen Testing?

2

What is the CAGR of the Pyrogen Testing Market?

3

Which test type leads the Pyrogen Testing Market?

4

Which region has the highest market share?

5

Which test type is growing the fastest?

6

What are the latest trends in the Pyrogen Testing Market?

7

Who are the key players in the Pyrogen Testing Market?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates